Wednesday, 08 December 2021

 

 

LATEST NEWS Charanjit Singh Channi Announces Heritage Street For Talwandi Sabo Charanjit Singh Channi Calls On Jathedar Sri Akal Takht Sahib Giani Harpreet Singh India announce 18-man squad for S Africa Tests, Rohit Sharma named ODI captain India players Mayank Agarwal and Ravichandran Ashwin make big progress in ICC Rankings Women's Asian Champions Trophy Hockey: India player tests Covid-positive, match vs Korea cancelled Usain Bolt's wish comes true, gets invited for T20 League Ashes, 1st Test: Rain ends play early after Cummins leads Australia in skittling out England for 147 UEFA Champions League: Real Madrid seal group leadership as Atletico book place in last-16 Novak Djokovic confirmed for ATP Cup; drops hint he will compete at Australian Open As England slump in opening Ashes Test, Ian Chappell says Joe Root not much of a captain Jude Bellingham fined by German FA for referee comments The Ashes, 1st Test: Pat Cummins leads the way as Australia skittle out England for 147 Winter Olympics: IOC does not foresee any situation to postpone Beijing 2022 Games 'Bigg Boss 15': Ex-contestant Neha Bhasin cheers for friend Shamita Shetty Ankita Lokhande injured ahead of her wedding, advised bed rest Manish Tewari seeks withdrawal of notification extending BSF jurisdiction in Punjab Jagat Prakash Nadda visits Swarnim Himachal Kala Mahotsav Jai Ram Thakur presided over a State Working Committee and Training programme "Punjab Minimum Wages Advisory Board" meets to fix minimum wages for workers 'KatVic' wedding: Wikipedia changes reversed after Vicky, Katrina named as spouses Ashwin Kumar Lakshmikanthan says he often dozes off during narration, directors livid

 

Diabetes drug can treat and reverse heart failure: Study

Web Admin

Web Admin

5 Dariya News

New York , 16 Nov 2020

Empagliflozin, a recently developed diabetes drug, can effectively treat and reverse heart failure in both diabetics and non-diabetics, say researchers.The clinical trial, published in the Journal of the American College of Cardiology, showed that this medication can improve the heart's size, shape, and function, leading to better exercise capacity and quality of life, which will reduce hospitalizations for heart failure patients. "Our clinical trial's promising results show this diabetes drug can ameliorate lives of heart failure patients with reduced ejection fraction, enhance their exercise capacity, and improve their quality of life with little to no side effects," said study author Carlos Santos-Gallego from Mount Sinai Hospital in the US."Our study also identifies why this drug is effective: because it improves heart function, something that has not been understood until now," Santos-Gallego added.Importantly, the researchers noted that the drug did not appear to cause hypoglycemia, or low blood sugar, in non-diabetic patients.For the trial, known as "EMPATROPISM," researchers recruited 84 patients with chronic heart failure with reduced ejection fraction (EF) -- the percentage of blood the left ventricle pumps with each contraction -- and randomized them to treatment with empagliflozin or a placebo.All had baseline evaluations including cardiac magnetic resonance imaging, a cardiopulmonary exercise test on a bicycle wearing a face mask to text oxygen levels, a six-minute walk test, and quality-of-life questionnaires.

Patients received treatment or placebo for six months, with some short safety visits at one and three months.At the six-month mark, patients went through the same tests.The researchers found that roughly 80 per cent of the patients treated with empagliflozin showed significant improvement, and their hearts returned to near normal.This group had a 16.6 per cent improvement in left ventricular ejection fraction at the six-month mark and their hearts pumped blood in a stronger way.Their hearts became smaller, less dilated because of less congestion and less fluid accumulation in the body, meaning that their heart failure became less severe, and the walls of the heart were less thick.The study also showed that patients taking empagliflozin had roughly 10 per cent improvement in their exercise levels, a statistically significant difference.This demonstrated that the empagliflozin group became healthier, could do more everyday activities, and had an improved quality of life, putting those patients at less risk of hospitalization."We were very surprised at how fast the benefits appeared with empagliflozin. The patients were already feeling better in the first few weeks of taking it," the authors wrote.

 

Tags: Health , Study , New York , Research , Researchers , World News , Diabetes , EMPATROPISM

 

 

related news

 

 

 

Photo Gallery

 

 

Video Gallery

 

 

5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2021 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD